Digitally enabled flash glucose monitoring for inpatients with COVID-19: Feasibility and pilot implementation in a teaching NHS Hospital in the UK
Open Access
- 7 January 2022
- journal article
- research article
- Published by SAGE Publications in Digital Health
Abstract
Background COVID-19 placed significant challenges on healthcare systems. People with diabetes are at high risk of severe COVID-19 with poor outcomes. We describe the first reported use of inpatient digital flash glucose monitoring devices in a UK NHS hospital to support management of people with diabetes hospitalized for COVID-19. Methods Inpatients at University Hospitals Coventry & Warwickshire (UHCW) NHS Trust with COVID-19 and diabetes were considered for digitally enabled flash glucose monitoring during their hospitalization. Glucose monitoring data were analysed, and potential associations were explored between relevant parameters, including time in hypoglycaemia, hyperglycaemia, and in range, glycated haemoglobin (HbA1c), average glucose, body mass index (BMI), and length of stay. Results During this pilot, digital flash glucose monitoring devices were offered to 25 inpatients, of whom 20 (type 2/type 1: 19/1; mean age: 70.6 years; mean HbA1c: 68.2 mmol/mol; mean BMI: 28.2 kg/m(2)) accepted and used these (80% uptake). In total, over 2788 h of flash glucose monitoring were recorded for these inpatients with COVID-19 and diabetes. Length of stay was not associated with any of the studied variables (all p-values >0.05). Percentage of time in hyperglycaemia exhibited significant associations with both percentage of time in hypoglycaemia and percentage of time in range, as well as with HbA1c (all p-values <0.05). The average glucose was significantly associated with percentage of time in hypoglycaemia, percentage of time in range, and HbA1c (all p-values <0.05). Discussion We report the first pilot inpatient use of digital flash glucose monitors in an NHS hospital to support care of inpatients with diabetes and COVID-19. Overall, there are strong arguments for the inpatient use of these devices in the COVID-19 setting, and the findings of this pilot demonstrate feasibility of this digitally enabled approach and support wider use for inpatients with diabetes and COVID-19.Funding Information
- HDR UK (HDR-3001)
- Winston Churchill Memorial Fellowship Trust (COVID-19 Action Fund)
This publication has 36 references indexed in Scilit:
- COVID-19 pandemic, coronaviruses, and diabetes mellitusAmerican Journal of Physiology-Endocrinology and Metabolism, 2020
- Practical recommendations for the management of diabetes in patients with COVID-19The Lancet Diabetes & Endocrinology, 2020
- Challenges for NHS hospitals during covid-19 epidemicBMJ, 2020
- COVID-19: protecting health-care workersThe Lancet, 2020
- Heterogeneity in Obesity: Genetic Basis and Metabolic ConsequencesCurrent Diabetes Reports, 2020
- Curcumin analog A13 alleviates oxidative stress by activating Nrf2/ARE pathway and ameliorates fibrosis in the myocardium of high-fat-diet and streptozotocin-induced diabetic ratsDiabetology & Metabolic Syndrome, 2020
- NHS England tells CCGs to end postcode lottery over diabetes glucose devicesPublished by BMJ ,2018
- Freestyle Libre Glucose Monitoring SystemClinical Diabetes, 2018
- Flash forward: a review of flash glucose monitoringDiabetic Medicine, 2018
- FreeStyle Libre Flash Glucose Self-Monitoring System: A Single-Technology Assessment2017